Oxygen-ozone therapy for myocardial ischemic stroke and cardiovascular disorders.
Sergio PandolfiSalvatore ChirumboloMarianno FranziniUmberto TirelliLuigi ValdenassiPublished in: Medical gas research (2024)
Cardiovascular diseases (CVDs) represent a major concern for human health worldwide. Emergencies in this field include wide repertories of studies dealing primarily with CVD prevention. In addition to dietary habits and lifestyles, medical knowledge is fully needed to improve public educational programs toward cardiovascular risk factors and to enrich the endowment of pharmaceutical options and therapies to address CVDs, particularly for ischemic damage due to an impairment in the endothelial-myocardial relationship. Because ozone is a stimulator of the endothelial nitric oxide synthase/nitric oxide pathway, ozone therapy has been widely demonstrated to have the ability to counteract endothelial-cardiac disorders, providing a novel straightforward opportunity to reduce the impact of CVDs, including atrial fibrillation. In this review, we attempt to establish a state-of-the-art method for the use of ozone in CVD, suggesting that future remarks be addressed to provide fundamental insights into this issue. The purpose of this study was to highlight the role of ozone in the adjunctive medical treatment of cardiovascular pathologies such as acute myocardial infarction due to ischemic disorders.
Keyphrases
- nitric oxide
- hydrogen peroxide
- nitric oxide synthase
- cardiovascular risk factors
- particulate matter
- healthcare
- left ventricular
- human health
- atrial fibrillation
- acute myocardial infarction
- cardiovascular disease
- endothelial cells
- risk assessment
- percutaneous coronary intervention
- metabolic syndrome
- left atrial
- heart failure
- public health
- climate change
- air pollution
- emergency department
- ischemia reperfusion injury
- type diabetes
- direct oral anticoagulants
- mesenchymal stem cells
- oral anticoagulants
- current status
- bone marrow
- venous thromboembolism
- mitral valve
- cell therapy